Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is standard therapy for head and neck squamous cell carcinoma (HNSCC). However, most HNSCC tumors are resistant to it and require alternative treatments. Here, we explored the mechanism of cetuximab resistance and evaluated its clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonesaka, Kimio, Tanaka, Kaoru, Kitano, Mutsukazu, Kawakami, Hisato, Hayashi, Hidetoshi, Takeda, Masayuki, Sakai, Kazuko, Nishio, Kazuto, Doi, Katsumi, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769016/
https://www.ncbi.nlm.nih.gov/pubmed/31570699
http://dx.doi.org/10.1038/s41389-019-0164-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769016/
https://www.ncbi.nlm.nih.gov/pubmed/31570699
http://dx.doi.org/10.1038/s41389-019-0164-9

Ejemplares similares